Guido Mastrantonio

Dr. Guido Mastrantonio

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2014 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
JAJaime Altcheh
Jaime Altcheh
GMGuillermo Moscatelli
Guillermo Moscatelli
GMGuido Mastrantonio
Guido Mastrantonio
SMSamanta Moroni
Samanta Moroni
NGNorberto Giglio
Norberto Giglio
FGFacundo García-Bournissen
Facundo García-Bournissen
Chagas disease, caused by the parasite Trypanosoma cruzi, can lead to long term cardiac morbidity. Treatment of children with benznidazole is effective, but no pediatric pharmacokinetics data are available and clinical pharmacology information on the drug is scarce. Prospective population pharmacokinetic (PK) cohort study in children 2–12 years old with Chagas disease treated with oral benznidazole 5–8 mg/kg/day BID for 60 days. (clinicaltrials.gov #NCT00699387). Forty children were enrolled in the study. Mean age was 7.3 years. A total of 117 samples were obtained from 38 patients for PK analysis. A one compartment model best fit the data. Weight-corrected clearance rate (CL/F) showed a good correlation with age, with younger patients having a significantly higher CL/F than older children and adults. Simulated median steady-state benznidazole concentrations, based on model parameters, were lower for children in our study than for adults and lowest for children under 7 years of age. Treatment was efficacious in the 37 patients who completed the treatment course, and well tolerated, with few, and mild, adverse drug reactions (ADRs). Observed benznidazole plasma concentrations in children were markedly lower than those previously reported in adults (treated with comparable mg/kg doses), possibly due to a higher CL/F in smaller children. These lower blood concentrations were nevertheless associated to a high therapeutic response in our cohort. Unlike adults, children have few adverse reactions to the drug, suggesting that there may be a direct correlation between drug concentrations and incidence of ADRs. Our results suggest that studies with lower doses in adults may be warranted. ClinicalTrails.gov NCT00699387 Chagas disease is a parasitic disease endemic to the Americas. Long term complications include severe cardiac involvement, which can lead to severe disability and death of affected individuals. Treatment options for Chagas disease are limited to 2 drugs (benznidazole and nifurtimox), but knowledge of the pharmacology of these drugs is lacking, particularly in childhood. To date, no pharmacokinetics data are available in children. We conducted the first population pharmacokinetic study of benznidazole in children. Interestingly, we found that elimination of the drug is significantly faster in children than in adults, leading to lower plasma concentrations. However, unlike adults, all children in the study responded well and had few adverse reactions to the drug. These findings suggest that adjustment of current adult doses may be beneficial.

1 March 2013 in Talanta
Verified
Journal Article
Open access
JPJ.M. Padró
J.M. Padró
MMM.E. Marsón
M.E. Marsón
GMGuido Mastrantonio
Guido Mastrantonio
JAJ. Altcheh
J. Altcheh
FGF. García-Bournissen
F. García-Bournissen
MRM. Reta
M. Reta
Dispersive ionic liquid-liquid microextraction combined with liquid chromatography and UV detection was used for the determination of two antichagasic drugs in human plasma: nifurtimox and benznidazole. The effects of experimental parameters on extraction efficiency-the type and volume of ionic liquid and disperser solvent, pH, nature and concentration of salt, and the time for centrifugation and extraction-were investigated and optimized. Matrix effects were detected and thus the standard addition method was used for quantification. This microextraction procedure yielded significant improvements over those previously reported in the literature and has several advantages, including high inter-day reproducibility (relative standard deviation=1.02% and 3.66% for nifurtimox and benznidazole, respectively), extremely low detection limits (15.7 ng mL(-1) and 26.5 ng mL(-1) for nifurtimox and benznidazole, respectively), and minimal amounts of sample and extraction solvent required. Recoveries were high (98.0% and 79.8% for nifurtimox and benznidazole, respectively). The proposed methodology offers the advantage of highly satisfactory performance in addition to being inexpensive, simple, and fast in the extraction and preconcentration of these antichagasic drugs from human-plasma samples, with these characteristics being consistent with the practicability requirements in current clinical research or within the context of therapeutic monitoring.

1 September 2001 in Forensic Science International
Verified
Journal Article
Closed access
LFLuis A Ferrari
Luis A Ferrari
MAMiriam G Arado
Miriam G Arado
LGLeda Giannuzzi
Leda Giannuzzi
GMGuido Mastrantonio
Guido Mastrantonio
MGManuel A Guatelli
Manuel A Guatelli

15 March 2016 in Memórias do Instituto Oswaldo Cruz
Verified
Journal Article
Open access
MFMarisa Liliana Fernández
Marisa Liliana Fernández
MMMaria Elena Marson
Maria Elena Marson
JRJuan Carlos Ramirez
Juan Carlos Ramirez
GMGuido Mastrantonio
Guido Mastrantonio
ASAlejandro Gabriel Schijman
Alejandro Gabriel Schijman
FBFacundo García Bournissen
Facundo García Bournissen
Pharmacological treatment of Chagas disease with benznidazole (BNZ) is effective in children in all stages, but it is controversial in chronically infected adults. We report the pharmacokinetics and pharmacodynamics in six adult patients with Chagas disease treated with the new BNZ formulation (ABARAX®) in doses between 2.5-5.5 mg/Kg/day. All but one patient had plasmatic BNZ concentrations within the expected range. All patients finalised treatment with nondetectable Trypanosoma cruzi quantitative polymerase chain reaction, which remained nondetectable at the six month follow-up. Our data suggests parasitological responses with the new BNZ and supports the hypothesis that treatment protocols with lower BNZ doses may be effective.

10 September 2014 in Archives of Disease in Childhood
Verified
Journal Article
Closed access
PDF file
FGFacundo García-Bournissen
Facundo García-Bournissen
SMSamanta Moroni
Samanta Moroni
MMMaria Elena Marson
Maria Elena Marson
GMGuillermo Moscatelli
Guillermo Moscatelli
GMGuido Mastrantonio
Guido Mastrantonio
JAJaime Altcheh
Jaime Altcheh
Background Benznidazole (BNZ) is safe and effective for the treatment of paediatric Chagas disease. Treatment of adults is also effective in many cases, but discouraged in breastfeeding women because no information on BNZ transfer into breast milk is available. We aimed to evaluate the degree of BNZ transfer into breast milk in lactating women with Chagas disease. Patients and methods Prospective cohort study of lactating women with Chagas disease treated with BNZ administered for 30 days. Patients and their breastfed infants were evaluated at admission, the 7th and 30th day of treatment (and monthly thereafter, for 6 months). BNZ was measured in plasma and milk by high performance liquid chromatography. The protocol was registered in ClinicalTrials.gov (#NCT01547533). Results 12 lactating women with chronic Chagas disease were enrolled (median age 28.5 years, range 20–34). Median BNZ dose was 5.65 mg/kg/day twice daily. Five mothers had adverse drug events (45%), but no adverse drug reactions or any untoward outcomes were observed in the breastfed infants. Median milk BNZ concentration was 3.8 mg/L (range 0.3–5.9) and 6.26 mg/L (range 0.3–12.6) in plasma. Median BNZ milk to plasma ratio was 0.52 (range 0.3–2.79). Median relative BNZ dose received by the infant (assuming a daily breast milk intake of 150 mL/kg/day) was 12.3% of the maternal dose per kg (range 5.5%–17%). Conclusions The limited transference of BNZ into breast milk and the reassuring normal clinical evaluation of the breastfed babies suggest that maternal BNZ treatment for Chagas disease during breast feeding is unlikely to present a risk for the breastfed infant. Trial registration number ClinicalTrials.gov NCT01547533.

1 January 2009 in Pediatric Drugs
Verified
Journal Article
Closed access
PDF file
FGFacundo Garcia-Bournissen
Facundo Garcia-Bournissen
JAJaime Altcheh
Jaime Altcheh
NGNorberto Giglio
Norberto Giglio
GMGuido Mastrantonio
Guido Mastrantonio
CVCarlos Omar Della Védova
Carlos Omar Della Védova
GKGideon Koren
Gideon Koren